WASHINGTON, DC—Further follow-up from the ALIGN-AR trial confirm the safety and continued efficacy of the Trilogy heart valve system (JenaValve) for the treatment of patients with severe, symptomatic ...
New research published in JSCAI and presented at New York Valves 2026 reports favorable one-year outcomes in patients with symptomatic severe aortic regurgitation following treatment with the ...
The FDA approved the Trilogy Transcatheter Heart Valve System for the treatment of symptomatic severe aortic regurgitation, device maker JenaValve Technology announced. This approval makes Trilogy the ...
Valvular regurgitation is when blood flows backward through the chambers of your heart. It can be mild and not cause symptoms, or it can be life threatening. Your heart is a muscular organ that ...
WASHINGTON — A phase 3 randomized trial will soon begin for the first transcatheter aortic valve replacement (TAVR) device for the treatment of aortic valve regurgitation after promising results in a ...
People with ankylosing spondylitis may be at an increased risk of developing some types of heart disease, including aortic regurgitation. Aortic regurgitation, or aortic insufficiency, is ...
Investigator-initiated study shows potential for EchoSolv AS to drive improved patient outcomes when used to support cardiologist in identifying severe AS particularly in women NEDA study of 1.2M ...
Background Congenital aortic stenosis (ConAoS) accounts for approximately 4%–8% of all congenital heart diseases. Chronic ...
The burden of severe aortic stenosis in the UK far exceeds the capacity of the NHS to screen or treat the disease, according to a study published this week in Open Heart. The study is the first to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results